RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $362.00. The company’s shares closed last Friday at $316.98. According to ...

Amgen Inc.'s Q3 earnings may not be a major upside, but new pipeline drugs and potential breakthroughs could drive growth.

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of ...

Choosing a random dividend stock out of a hat won't do, though. Some are much more attractive than others. Which ones should ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

An investor is suing Amgen Inc.'s leaders over the company’s $10.7 billion fight with the IRS, which has said the ...

Amgen is a significant win for IPG Mediabrands after Amazon moved its massive media business from Initiative to WPP and ...